Tamoxifen

89 interactions 5 explained in plain English

Also sold as: Nolvadex® Soltamox Soltamox®

About Tamoxifen

Tamoxifen is an antiestrogen medication used to treat breast cancer and reduce the risk of developing it in high-risk women. Read the full Tamoxifen drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Lefamulin Oxaliplatin Injection Dasatinib Sertraline Ofloxacin

2 Contraindicated 81 Major 6 Moderate

All (89) Contraindicated (2) Major (81) Moderate (6)

Contraindicated

Tamoxifen Ketoconazole Topical Extina® Foam Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Tamoxifen Lefamulin Xenleta Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details

Major

Tamoxifen Abametapir Explained Increased exposure of CYP3A4 substrate Details Tamoxifen Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Tamoxifen Sertraline Explained Reduced exposure of active tamoxifen metabolites and an increased risk of QT interval prolongation Details Tamoxifen Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Tamoxifen Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Tamoxifen Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Tamoxifen Anastrozole Arimidex Reduced anastrozole exposure Details Tamoxifen Arsenic Trioxide Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Tamoxifen Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Tamoxifen Arsenic Trioxide Injection Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Tamoxifen Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Tamoxifen Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Tamoxifen Azathioprine Azasan An increased risk of hepatotoxicity Details Tamoxifen Azithromycin AzaSite An increased risk of QT interval prolongation and torsade de pointes Details Tamoxifen Abiraterone Abirtega Increased tamoxifen exposure, increased risk of tamoxifen-related adverse effects or reduced tamoxifen efficacy Details Tamoxifen Alfuzosin UroXatral An increased risk of QT interval prolongation Details Tamoxifen Anagrelide Agrylin Increased risk of QT interval prolongation Details Tamoxifen Bedaquiline Sirturo Increased risk of QT interval prolongation Details Tamoxifen Capecitabine Xeloda An increased risk of thromboembolism Details Tamoxifen Chloroquine Aralen® Increased risk of retinopathy and increased risk of QT-interval prolongation Details Tamoxifen Cyclophosphamide Cytoxan® An increased risk of thromboembolism Details Tamoxifen Cyclophosphamide Injection Cytoxan® Injection An increased risk of thromboembolism Details Tamoxifen Dacomitinib Vizimpro Increased exposure of the CYP2D6 substrate Details Tamoxifen Dasatinib Phyrago An increased risk of QT interval prolongation Details Tamoxifen Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Tamoxifen Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Tamoxifen Disopyramide Norpace An increased risk of QT interval prolongation Details Tamoxifen Dofetilide Tikosyn An increased risk of QT interval prolongation Details Tamoxifen Dolasetron Anzemet An increased risk of QT interval prolongation Details Tamoxifen Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Tamoxifen Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Tamoxifen Encorafenib Braftovi Increased risk of QT interval prolongation Details Tamoxifen Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Tamoxifen Eribulin Injection Halaven An increased risk of QT interval prolongation Details Tamoxifen Famotidine Calmicid An increased risk of QT interval prolongation Details Tamoxifen Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Tamoxifen Felbamate Felbatol An increased risk of QT interval prolongation Details Tamoxifen Flecainide Tambocor® An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.